Biotechnology Assets (XMAD:BST) Scaled Net Operating Assets: 0.77 (As of Dec. 2025)


XMAD:BST Biotechnology Assets SA XMAD:BST
19 GF Score
Price €0.23
GF Value €0.30
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biotechnology Assets Scaled Net Operating Assets?

Biotechnology Assets XMAD:BST -4.24% 19 Scaled Net Operating Assets is 0.77 as of Dec. 2025. GuruFocus rates XMAD:BST with a GF Score™ of 19/100 and a GF Value™ of €0.30 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Biotechnology Assets's operating assets for the quarter that ended in Dec. 2025 was €12.97 Mil. Biotechnology Assets's operating liabilities for the quarter that ended in Dec. 2025 was €2.60 Mil. Biotechnology Assets's Total Assets for the quarter that ended in Jun. 2025 was €13.46 Mil. Therefore, Biotechnology Assets's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.77.

Biotechnology Assets Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Biotechnology Assets's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotechnology Assets Scaled Net Operating Assets Chart

Biotechnology Assets Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.75 0.72 0.70 0.70

Biotechnology Assets Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.54 0.77 0.71 0.77

XMAD:BST vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Biotechnology Assets's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotechnology Assets Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Biotechnology Assets's Scaled Net Operating Assets falls into.


XMAD:BST
19GF Score
Biotechnology Assets SA XMAD:BST
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biotechnology Assets Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Biotechnology Assets's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(12.969-2.595)/14.784
=0.70

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=13.563 - 0.594
=12.969

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=6.601 - 2.301 - 1.705
=2.595

Biotechnology Assets's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Jun. 2025 )
=(12.969-2.595)/13.458
=0.77

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=13.563 - 0.594
=12.969

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=6.601 - 2.301 - 1.705
=2.595

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.77 mean?
Biotechnology Assets (XMAD:BST) has a Scaled Net Operating Assets of 0.77 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Biotechnology Assets and its competitors.
Is Biotechnology Assets' Scaled Net Operating Assets too high?
Biotechnology Assets' current Scaled Net Operating Assets is 0.77. Overall, Biotechnology Assets has a GF Score™ of 19/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' Scaled Net Operating Assets compare to VRTX and REGN?
Biotechnology Assets' Scaled Net Operating Assets of 0.77 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Biotechnology Assets and its competitors. Biotechnology Assets's current Scaled Net Operating Assets is 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.30, compared to a current price of €0.23 — trading 24.7% below its estimated fair value. The current Scaled Net Operating Assets is 0.77. Biotechnology Assets' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current Scaled Net Operating Assets is 0.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?

Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued. The current stock price of €0.23 is trading 24.7% below its estimated GF Value™ of €0.30. GuruFocus considers Biotechnology Assets to be Modestly Undervalued.

Key valuation signals for XMAD:BST:

  • Scaled Net Operating Assets: 0.77
  • GF Value™: €0.30 vs. price of €0.23 (24.7% below fair value)
  • GF Score™: 19/100 with 3 warning signs

No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biotechnology Assets Business Description

Address Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
19GF Score

Get the complete analysis for XMAD:BST

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.23
Price
€0.30
GF Value